Related Experiment Video
Updated: May 30, 2026

Isolation of Soluble and Insoluble PrP Oligomers in the Normal Human Brain
Published on: October 3, 2012
Insoluble cellular prion protein and its association with prion and Alzheimer diseases
Wen-Quan Zou1, Xiaochen Zhou, Jue Yuan
1Department of Pathology, National Prion Disease Pathology Surveillance Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA. wenquan.zou@case.edu
Abstract:
The soluble cellular prion protein (PrP(C)) is best known for its association with prion disease (PrD) through its conversion to a pathogenic insoluble isoform (PrP(Sc)). However, its deleterious effects independent of PrP(Sc) have recently been observed not only in PrD but also in Alzheimer disease (AD), two diseases which mainly affect cognition. At the same time, PrP(C) itself seems to have broad physiologic functions including involvement in cognitive processes. The PrP(C) that is believed to be soluble and monomeric has so far been the only PrP conformer observed in the uninfected brain. In 2006, we identified an insoluble PrP(C) conformer (termed iPrP(C) ) in uninfected human and animal brains. Remarkably, the PrP(Sc) -like iPrPC shares the immunoreactivity behavior and fragmentation with a newly-identified PrP(Sc) species in a novel human PrD termed variably protease-sensitive prionopathy. Moreover, iPrP(C) has been observed as the major PrP species that interacts with amyloid β (Aβ) in AD. This article highlights evidence of PrP involvement in two putatively beneficial and deleterious PrP-implicated pathways in cognition, and hypothesizes first, that beneficial and deleterious effects of PrP(C) are attributable to the chameleon-like conformation of the protein and second, that the iPrP(C) conformer is associated with PrD and AD.
Insights
Cellular prion protein (PrP(C)) has dual roles in cognition. Its conformation dictates whether PrP(C) is beneficial or detrimental, with insoluble PrP(C) linked to prion and Alzheimer diseases.
Area of Science:
- Neuroscience
- Biochemistry
- Prion Biology
Background:
- Soluble cellular prion protein (PrP(C)) is known for its role in prion disease (PrD) via conversion to insoluble PrP(Sc).
- PrP(C) also exhibits deleterious effects independent of PrP(Sc) in PrD and Alzheimer disease (AD), both impacting cognition.
- PrP(C) has physiological functions, including involvement in cognitive processes.
Purpose of the Study:
- To highlight evidence of PrP involvement in beneficial and deleterious pathways affecting cognition.
- To hypothesize that PrP(C)'s conformation determines its beneficial or detrimental effects.
- To propose that insoluble PrP(C) (iPrP(C)) is associated with PrD and AD.
Main Methods:
- Identification of an insoluble PrP(C) conformer (iPrP(C)) in uninfected brains.
- Comparison of iPrP(C) immunoreactivity and fragmentation with PrP(Sc) species in variably protease-sensitive prionopathy.
- Observation of iPrP(C) interaction with amyloid-beta (Aβ) in AD.
Main Results:
- An insoluble PrP(C) conformer (iPrP(C)) was identified in uninfected human and animal brains.
- iPrP(C) shares characteristics with PrP(Sc) in variably protease-sensitive prionopathy.
- iPrP(C) is the primary PrP species interacting with Aβ in AD.
Conclusions:
- PrP(C)'s beneficial and deleterious effects in cognition are linked to its conformational flexibility.
- The insoluble PrP(C) (iPrP(C)) conformer is associated with prion disease and Alzheimer disease.
- Understanding PrP(C) conformation is crucial for deciphering its role in neurological disorders.
More Related Videos
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology
Alzheimer Disease l: Introduction
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Subviral Agents

